tickrz reports
tickrz rank
D
Alexion Pharmaceuticals Inc (ALXN)
Healthcare | Drugs
142.89  -0.07%
FACTOR RANKINGSFACTOR SCREENER 
tickrz RankD / 431Warren Buffett RankD / 465
Pure Value RankD / 438Dividend RankD / NO DIVIDEND
Moat RankC / 304Financial Strength RankA / 95
Growth RankA / 17Momentum RankC / 329
ALXN vs DRUGS SECTOR & S&P 500
VALUATION
ALXNSECTORS&P 500
P/E RATIO63.2335.719.28
EV/EBITDA RATIO30.425.111.77
P/S RATIO9.677.12.03
P/B RATIO3.728.73.09
QUALITY
RETURN ON EQUITY6.11%16.98%13.82%
RETURN ON CAPITAL5.53%26.23%10.04%
NET MARGIN13.25%14.46%9.76%
DIVIDEND ANALYSIS
DIVIDEND YIELD
0%
PAYOUT RATION/A
3 YR DIVIDEND GROWTHN/A
FINANCIAL STRENGTH
PIOTROSKI F SCORE
6 OUT OF 9
DEBT-TO-EQUITY37%
INTEREST COVERAGE7.42x
CURRENT RATIO3.26
GROWTH
5 YR EPS GROWTH14.1%
5 YR SPS GROWTH30.68%
5 YR BPS GROWTH44.71%
About tickrz
Key Concepts
Great Investors
Alexion Pharmaceuticals Inc 's strong growth translates to a Growth Rank in the top 25% of all stocks
tickrz rank D / 431
Alexion Pharmaceuticals Inc receives a D ranking in our proprietary ranking system that combines valuation, moat, operational performance, and financial strength. View the Top 50 tickrz ranked stocks here.
value
pure value ranking D / 438Warren Buffett ranking D / 465
Valuation is the most heavily weighted component in our tickrz ranking methodology. Numerous academic and practitioner studies have found that a value approach outperforms the market over the long-run. Alexion Pharmaceuticals Inc's valuation score is comprised of a P/E ratio of 63.2x, a P/B ratio of 3.7x, a P/S ratio of 9.7x, and an EV/EBITDA ratio of 30.4x. Alexion Pharmaceuticals Inc ranks 438 out of the S&P 500 constituents on valuation--a relatively weak score.Alexion Pharmaceuticals Inc ranks 465 out of the S&P 500 constituents in our multi-factor Warren Buffett ranking methodology. This is a weak score, meaning it ranks poorly on valuation, moat, volatility, and financial strength factors. If you're looking for undervalued stocks with high moats and strong competitive advantages, Alexion Pharmaceuticals Inc is probably not for you.

quality
moat C / 304financial strength A / 95
To calculate a company's Moat Score, we look at its historical earnings growth, historical average return on equity, the volatility of its earnings stream, and also factor in the strength of its balance sheet. Our approach concludes the company's business moat is weak. Its position within the Healthcare sector appears to be weak. Either the dynamics of its sector place it in a difficult position or management's executition is to blame for its disappointing performance.Alexion Pharmaceuticals Inc has a Piotroski F Score of 6 out of 9. The F Score examines changes in profitability, leverage, liquidity, and operating efficiency. Interest coverage of 7.42x, a debt/equity ratio of 37% and a Moat Rank of 304 translate to a strong Financial Strength score.


momentum C / 329
Investment research has shown that stocks with strong performance over the last 6 to 12 months tend to perform better in the medium term than stocks with poor performance over the same period. In fact, the momentum factor is one of the strongest of all the investment factors. The company has seen its stock appreciate by 4.25% over the last 12 months. This performance is weak compared to other stocks in the S&P 500, earning it a rank of 329. Based on its 12 month stock performance, Alexion Pharmaceuticals Inc will not appeal to momentum investors.

yield D / NO DIVIDEND
value + yield
Alexion Pharmaceuticals Inc currently does not pay a dividend so it ranks last among S&P 500 companies using our dividend ranking methodology. Investors looking for undervalued dividend stocks will probably want to look elsewhere.

growth A / 17
A company's growth metrics are less important than its valuation, moat, and financial strength. However, a check on growth can be a good way to avoid companies in secular decline. The company's growth in sales, earnings, and book value places it among the top third of S&P 500 companies. Its 14.1% 5 year annualized EPS growth, 30.7% 5 year annualized sales-per-share growth, and 5 year annualized book value-per-share growth of 44.7% speak to its impressive growth ranking.

Alexion Pharmaceuticals Inc (ALXN)
Healthcare | Drugs
142.89  -0.07%


tickrz rank
D
VALUATION RATIOS
P/E Ratio63.23x
P/B Ratio3.72x
P/S Ratio9.67x
EV/EBITDA Ratio30.4x
DIVIDEND ANALYSIS
DIVIDEND YIELD
0%
PAYOUT RATION/A
3 YR DIVIDEND GROWTHN/A
FINANCIAL STRENGTH
PIOTROSKI F SCORE
6 OUT OF 9
DEBT-TO-EQUITY37%
INTEREST COVERAGE7.42x
CURRENT RATIO3.26
MOAT
ROE6.11%
ROIC5.53%
Net Margin13.25%
GROWTH
5 YR EPS GROWTH14.1%
5 YR SPS GROWTH30.68%
5 YR BPS GROWTH44.71%

TICKRZ RANK
Alexion Pharmaceuticals Inc receives a D ranking in our proprietary ranking system that combines valuation, moat, operational performance, and financial strength. View the Top 50 tickrz ranked stocks here.

PURE VALUE
Valuation is the most heavily weighted component in our tickrz ranking methodology. Numerous academic and practitioner studies have found that a value approach outperforms the market over the long-run. Alexion Pharmaceuticals Inc's valuation score is comprised of a P/E ratio of 63.2x, a P/B ratio of 3.7x, a P/S ratio of 9.7x, and an EV/EBITDA ratio of 30.4x. Alexion Pharmaceuticals Inc ranks 438 out of the S&P 500 constituents on valuation--a relatively weak score.

WARREN BUFFETT RANKING
Alexion Pharmaceuticals Inc ranks 465 out of the S&P 500 constituents in our multi-factor Warren Buffett ranking methodology. This is a weak score, meaning it ranks poorly on valuation, moat, volatility, and financial strength factors. If you're looking for undervalued stocks with high moats and strong competitive advantages, Alexion Pharmaceuticals Inc is probably not for you.

MOAT
To calculate a company's Moat Score, we look at its historical earnings growth, historical average return on equity, the volatility of its earnings stream, and also factor in the strength of its balance sheet. Our approach concludes the company's business moat is weak. Its position within the Healthcare sector appears to be weak. Either the dynamics of its sector place it in a difficult position or management's executition is to blame for its disappointing performance.

FINANCIAL STRENGTH
Alexion Pharmaceuticals Inc has a Piotroski F Score of 6 out of 9. The F Score examines changes in profitability, leverage, liquidity, and operating efficiency. Interest coverage of 7.42x, a debt/equity ratio of 37% and a Moat Rank of 304 translate to a strong Financial Strength score.

MOMENTUM
Investment research has shown that stocks with strong performance over the last 6 to 12 months tend to perform better in the medium term than stocks with poor performance over the same period. In fact, the momentum factor is one of the strongest of all the investment factors. The company has seen its stock appreciate by 4.25% over the last 12 months. This performance is weak compared to other stocks in the S&P 500, earning it a rank of 329. Based on its 12 month stock performance, Alexion Pharmaceuticals Inc will not appeal to momentum investors.

VALUE + YIELD
Alexion Pharmaceuticals Inc currently does not pay a dividend so it ranks last among S&P 500 companies using our dividend ranking methodology. Investors looking for undervalued dividend stocks will probably want to look elsewhere.

GROWTH
A company's growth metrics are less important than its valuation, moat, and financial strength. However, a check on growth can be a good way to avoid companies in secular decline. The company's growth in sales, earnings, and book value places it among the top third of S&P 500 companies. Its 14.1% 5 year annualized EPS growth, 30.7% 5 year annualized sales-per-share growth, and 5 year annualized book value-per-share growth of 44.7% speak to its impressive growth ranking.